Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
Zacks
More News
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
Zacks
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
HeartFlow (HTFL) delivered earnings and revenue surprises of +50.00% and +12.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Zacks
Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now
Cooper Companies' premium lens migration, MiSight growth and fertility recovery offer long-term upside despite Asia-Pacific, tariff and FX pressures.
Zacks
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of +47.62% and +3.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.
Zacks
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
Zacks
CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.